NICE Gives Thumbs Up to Three Diabetes Drugs

The UK’s National Institute for Health Care Excellence finalized earlier recommendations for three Type 2 diabetes drugs as monotherapies.

In final guidance posted last week, the UK cost watchdog backed NIH coverage for Invokana from Janssen, Forxiga by AstraZeneca and Jardiance, which is jointly sponsored by Boehringer Ingelheim and Eli Lilly.

The recommendation applies to adult patients when metformin, pioglitazone or sulfonylureas are not adequate options.

Forxiga and Jardiance both have the same list price of $53.80 for a 28-tablet pack, while the list price for Invokana is $57.64 for a 30-tablet pack.